Global Viral Antigen Diagnostics Market – Industry Trends and Forecast to 2030

Viral Antigen Diagnostics Market Analysis and Size

The high adoption of viral antigens in vaccine expansion by clinicians and researchers has been increasing on a significant pace, thereby motivating as well as lifting the growth of the global viral antigen diagnostics market. In addition, the advancements in image analysis software and informatics platforms for viral antigen detection further propels the high adoption rate of solutions offered in the market for molecular biology kits and reagents. Also the rising incidence of viral infections, clinical research and technological advances in molecular diagnostics is also fuelling the demand of the global viral antigen diagnostics market over the forecast period of 2023 to 2030. The rapid advancement in both science and technology is also exceedingly influencing the growth of the global viral antigen diagnostics market.

Data Bridge Market Research analyses that the global viral antigen diagnostics market which was USD 14.17 billion in 2022, is expected to reach USD 27.03 billion by 2030, and is expected to undergo a CAGR of 7.9% during the forecast period 2023-2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Viral Antigen Diagnostics Market Scope and Segmentation

Market Definition

Viral antigen diagnostics is a method used in medical testing to detect the presence of specific viral proteins, known as antigens, in a patient's sample, typically collected from bodily fluids like nasal swabs or blood. These antigens are unique to the virus being targeted and are part of the virus's structure. The diagnostic process involves using specialized tests, such as enzyme-linked immunosorbent assays (ELISAs) or rapid antigen tests, to identify and quantify these viral antigens.

Global Viral Antigen Diagnostics Market Dynamics

Driver

• Growing Focus of Vaccine Monitoring

In the wake of extensive vaccination campaigns against viral diseases such as COVID-19 and the continued need for vaccination against diseases like influenza, viral antigen diagnostics have gained prominence in vaccine monitoring efforts. These diagnostics play a pivotal role in several key aspects of vaccine deployment and management. Firstly, they are used to assess vaccine efficacy by detecting the presence of viral antigens in individuals after vaccination. This is particularly important for vaccines that aim to prevent infections by specific viruses, like SARS-CoV-2, the virus responsible for COVID-19. Monitoring the presence of viral antigens through antigen tests helps health authorities evaluate how well a vaccine is working in real-world conditions.

Opportunity

• Rapidly Increasing Demand of Remote Healthcare

The rapid expansion of telemedicine and remote healthcare services is creating substantial market opportunities for viral antigen diagnostics. As these digital healthcare solutions continue to gain momentum, the demand for efficient and accessible diagnostic tools has surged. Telemedicine platforms, which allow patients to consult with healthcare professionals remotely, often require swift diagnostic results to guide treatment decisions. Viral antigen tests, known for their speed and simplicity, are integral in this context, enabling timely diagnoses and facilitating virtual patient-doctor interactions.

Moreover, the growth of telehealth has extended beyond routine consultations, with a notable focus on managing chronic conditions and providing mental health support remotely. In these scenarios, viral antigen diagnostics play a critical role in monitoring patients, detecting viral infections, and ensuring prompt interventions, all from the comfort of their homes. 

Restraint/Challenge

• Regulatory Hurdles and Quality Control Challenges

The development and commercialization of viral antigen diagnostic tests must adhere to stringent regulatory requirements to ensure their safety and accuracy. Meeting these regulatory standards, such as those set by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), can be time-consuming and costly. Additionally, maintaining consistent quality control during the production and distribution of these tests is essential to prevent false results that could have serious implications for patient care and public health.

Complying with these regulations and quality control standards can be a significant barrier for both established companies and startups in the global viral antigen diagnostics market. The need for rigorous testing, validation, and documentation adds complexity and expenses to the development process. Any regulatory delays or quality control issues can hinder market entry or lead to product recalls, damaging a company's reputation and financial performance. Therefore, while the market offers opportunities, navigating the regulatory landscape and ensuring stringent quality control are essential challenges that companies must overcome.

This global viral antigen diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global viral antigen diagnostics market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2020, Seven million of Abbott's rapid ID tests have been delivered to all 50 states, Washington, D.C., Puerto Rico, and the Pacific Islands. Customers are urged to give frontline healthcare providers and first responders priority because the majority of these tests have been sent to outbreak hotspots
• In July 2020, BD dramatically increased the availability of COVID-19 testing by launching a portable, quick point-of-care antigen test to detect SARS-CoV-2 in 15 minutes

 Global Viral Antigen Diagnostics Market Scope

The global viral antigen diagnostics market is segmented on the basis of diagnosis test, virus type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis Test

• Specimen Examination
• Serodiagnostic Tests
• Viral Isolation

 Virus Type

• Adenovirus
• Cytomegalovirus
• Dengue Virus
• Enterovirus
• Hepatitis Virus
• HIV-1
• Coronavirus
• Human Metapneumovirus
• Human Rhinovirus A
• Measles Virus
• Poliovirus
• Rabies Virus
• Varicella Zoster Virus
• Avian Influenza
• Coxsackievirus
• Epstein-Barr Virus (EBV)
• Lymphocryptovirus
• Herpes Virus (HSV-1, HSV-2)
• HIV-2
• Human Herpesvirus
• Human Papillomavirus (HPV)
• Influenza Virus
• Mumps Virus
• Rubella Virus
• Respiratory Syncytial Virus (RSV)
• West Nile Virus

End User

• Physician Offices
• Commercial Laboratories
• Nursing Homes

Global Viral Antigen Diagnostics Market Analysis/Insights

The global viral antigen diagnostics market is analysed and market size insights and trends are provided by country, test, virus type, and end user as referenced above.  

The countries covered in the global viral antigen diagnostics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America is dominating and is expected to witness significant growth in the global viral antigen diagnostics market due high demand from consumer sector.   

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the Market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Viral Antigen Diagnostics Market Share Analysis

The global viral antigen diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global viral antigen diagnostics market.  

Some of the major players operating in the global viral antigen diagnostics market are:

• Abbott (U.S.)
• Cepheid (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• The Native Antigen Company (U.K.)
• Thermo Fischer Scientific, Inc (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• bioMerieux SA (France)
• DiaSorin S.p.A (Italy)
• Merck KGaA (Germany)
• Quidel Corporation (U.S.)
• Randox Laboratories Ltd (U.K.)
• CorisBioConcept SPRL (Belgium)
• Bio-Rad Laboratories, Inc (U.S.)
• Creative Diagnostics (U.S.)
• Fast Track Diagnostics (Luxembourg)
• Quest Diagnostics (U.S.)
• BD (Becton, Dickinson and Company) (U.S.)
• OraSure Technologies (U.S.)
• Novartis AG (Switzerland)
• Siemens (Germany)

SKU-57425